NCT00288444

Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer

Defining the Interaction of Docetaxel and Lonafarnib in Patients With Advanced Malignancies

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: Emory University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

To determine the molecular interaction in tumor samples between docetaxel and lonafarnib.

Detailed description

1. To determine the safety and toxicity of intravenous docetaxel, administered on a weekly schedule (3 weeks out of 4), in combination with oral lonafarnib, administered on a daily schedule, in patients with locally advanced and metastatic solid tumor malignancies which are refractory to the standard of care. 2. To determine the pharmacokinetic interaction between docetaxel and lonafarnib. 3. To determine the molecular interaction in peripheral blood mononuclear cells between docetaxel and lonafarnib

Conditions

• Lung Cancer
• Soft Tissue Sarcoma
• Colorectal Carcinoma
• Breast Cancer
• Prostate Cancer

Interventions

Type	Name	Description
DRUG	Lonafarnib
DRUG	Docetaxel

Timeline

• Start date: 2006-01-01
• Primary completion: 2008-05-01
• Completion: 2009-03-01
• First posted: 2006-02-08
• Last updated: 2012-12-18

Locations

1 site across 1 country: United States